Fylnetra Injection
FDA Label NDC 70121-1627

39 label sections · Submitted to the FDA by Amneal Pharmaceuticals Llc · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Amneal Pharmaceuticals Llc for the product Fylnetra (NDC 70121-1627). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1.1 patients with cancer receiving myelosuppressive chemotherapy, 1.2 patients with hematopoietic subsyndrome of acute radiation syndrome, 2.1 patients with cancer receiving myelosuppressive chemotherapy, 2.2 patients with hematopoietic subsyndrome of acute radiation  syndrome, 2.3 administration, 3 dosage forms and strengths, 4 contraindications, 5.1 splenic rupture, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.